Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 11/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3576909 | 0.82 | CCR5 (0.53) | CCR5KMT2AKCNH2 | |
| SCHEMBL4925891 | 0.82 | CCR5 (0.55) | CCR5SIGMAR1ALDH1A1LMNA | |
| SCHEMBL12359048 | 0.81 | CCR5 (0.69) | CCR5KMT2ASIGMAR1KCNH2 | |
| Hydrochloric Acid SCHEMBL4209085 | 0.81 | CCR5 (0.54) | CCR5SIGMAR1ALDH1A1LMNA | |
| SCHEMBL27879571 | 0.81 | CCR5 (0.54) | CCR5KMT2ASIGMAR1ALDH1A1LMNA | |
| SCHEMBL3931865 | 0.81 | ALDH1A1 (0.69) | CCR5KMT2AALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL27712294 | 0.80 | CCR5 (0.53) | CCR5KMT2ASIGMAR1ALDH1A1LMNA | |
| SCHEMBL16625302 | 0.80 | CCR5 (0.51) | CCR5KMT2AKCNH2 | |
| SCHEMBL3048764 | 0.80 | CCR5 (0.71) | CCR5KMT2AKCNH2 | |
| Hydrochloric Acid SCHEMBL3035507 | 0.79 | CCR5 (0.70) | CCR5KMT2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2109605-B1 | 2- [(PHENYLAMINO) -PYRIMIDIN-4YLAMIN0] -CYCLOPENTANE CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF KINASES OF THE CELL CYCLE FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2013-02-20 | — | — | EP | disclosed |
| US-20100144706-A1 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144706-A1 | Compounds | MKI67, CCNA1, CCNT1 | CCR5 1629/4885KMT2A 3248/4885SIGMAR1 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.